MTDHP4

Across TCGA pan-cancer cohorts, MTDHP4 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated MTDHP4 data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MTDHP4 RNA is associated with better overall survival. In most high-consensus cancer types, elevated MTDHP4 expression acts as an unfavorable survival marker, although some lineages such as OV and MESO show a favorable association.

OV, MESO, and BLCA are the cancer types where MTDHP4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	All	0.748	0.636	<.001	118	view →
MESO	DFS	Median	III,IV	0.513	0.299	.007	48	view →
BLCA	OS	Tertile	II,III,IV	0.690	0.548	.004	43	view →
HNSC	DFS	Tertile	IV	0.774	0.614	.003	38	view →
SARC	OS	Median	All	0.885	0.792	.001	33	view →
PRAD	DFS	Quartile	All	0.888	0.955	<.001	28	view →
PCPG	DFS	Quartile	All	0.592	1.000	<.001	21	view →
CESC	DFS	Tertile	II,III,IV	0.804	0.606	.020	20	view →
LIHC	OS	Tertile	All	0.399	0.607	<.001	20	view →
ACC	DFS	Quartile	II,III,IV	0.742	0.282	.013	19	view →
CHOL	DFS	Median	II,III,IV	0.106	0.511	.011	12	view →
GBM	OS	Median	All	0.487	0.331	.012	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

MTDHP4–OV (OS)

Open the OV breakdown →